SNDX - Company ID 0001395937
Syndax Pharmaceuticals Inc (SNDX) reported net income of -$285.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$285.40M | +10.5% |
| FY 2024 | -$318.80M | -52.2% |
| FY 2023 | -$209.40M | -40.3% |
| FY 2022 | -$149.30M | -699.6% |
| FY 2021 | $24.90M | +134.0% |
| FY 2020 | -$73.16M | -30.5% |
| FY 2019 | -$56.05M | +24.2% |
| FY 2018 | -$73.96M | -21.6% |
| FY 2017 |
Syndax Pharmaceuticals Inc (SNDX) reported net income of -$285.40M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Syndax Pharmaceuticals Inc's net income declined from -$19.83M to -$285.40M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$60.80M |
| -36.7% |
| FY 2016 | -$44.47M | -84.4% |
| FY 2015 | -$24.12M | -21.6% |
| FY 2014 | -$19.83M | - |